Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

Follow Drugslib on

By I. Edwards HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 18, 2025.

via HealthDay

WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.

The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported.

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as much as $300 million more if Verve’s top drug hits certain research milestones. That would bring the total deal $1.3 billion, The WSJ reported.

Verve’s board has agreed to the sale and recommends that shareholders support the decision. The deal is expected to close by the third quarter of this year.

Verve is developing a new class of gene-editing drugs that could be given just once to treat chronic conditions. Its top drug — Verve-102 — is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

The treatment is being tested in a Phase 1b clinical trial and has received fast-track designation from the U.S. Food and Drug Administration (FDA), The WSJ added.

“Verve-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,” Ruth Gimeno, Lilly’s vice president of metabolic and diabetes drug development, said.

If the drug passes early trials and moves into a Phase 3 trial, Verve shareholders will receive an additional $3 per share. That payout would happen if the first patient receives the treatment within 10 years of the deal closing.

Verve’s co-founder and CEO, Dr. Sekar Kathiresan, said the company was created with a bold goal: to change how heart disease is treated.

“In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic,” he told The WSJ. “Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly.”

Sources

  • The Wall Street Journal, June 17, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-06-19 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords